

PARG Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP16714b**Specification**

PARG Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [Q86W56](#)**PARG Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 670;8505**Other Names**

Poly(ADP-ribose) glycohydrolase, PARG

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PARG Antibody (C-term) Blocking Peptide - Protein Information**Name** PARG {ECO:0000303|PubMed:14527731, ECO:0000312|HGNC:HGNC:8605}**Function**

Poly(ADP-ribose) glycohydrolase that degrades poly(ADP- ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP- ribose) (PubMed:15450800, PubMed:21892188, PubMed:23102699, PubMed:23474714, PubMed:33186521, PubMed:34321462, PubMed:34019811). PARG acts both as an endo- and exoglycosidase, releasing poly(ADP- ribose) of different length as well as ADP-ribose monomers (PubMed:23102699, PubMed:23481255). It is however unable to cleave the ester bond between the terminal ADP-ribose and ADP-ribosylated residues, leaving proteins that are mono-ADP-ribosylated (PubMed:21892188, PubMed:23474714, PubMed:33186521). Poly(ADP-ribose) is synthesized after DNA damage is only present transiently and is rapidly

degraded by PARG (PubMed:23102699, PubMed:34019811). Required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress, while it is not required for recovery from transient replicative stress (PubMed:24906880). Responsible for the prevalence of mono-ADP-ribosylated proteins in cells, thanks to its ability to degrade poly(ADP-ribose) without cleaving the terminal protein-ribose bond (PubMed:33186521). Required for retinoid acid- dependent gene transactivation, probably by removing poly(ADP-ribose) from histone demethylase KDM4D, allowing chromatin derepression at RAR- dependent gene promoters (PubMed:23102699). Involved in the synthesis of ATP in the nucleus, together with PARP1, NMNAT1 and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257).

Cellular Location

[Isoform 1]: Nucleus Note=Colocalizes with PCNA at replication foci (PubMed:21398629)
Relocalizes to the cytoplasm in response to DNA damage (PubMed:16460818). [Isoform 3]:
Cytoplasm [Isoform 5]: Mitochondrion matrix

Tissue Location

Ubiquitously expressed.

PARG Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

PARG Antibody (C-term) Blocking Peptide - Images

PARG Antibody (C-term) Blocking Peptide - Background

Poly(ADP-ribose) glycohydrolase (PARG) is the majorenzyme responsible for the catabolism of poly(ADP-ribose), areversible covalent-modifier of chromosomal proteins. The proteinis found in many tissues and may be subject to proteolysisgenerating smaller, active products.

PARG Antibody (C-term) Blocking Peptide - References

Whatcott, C.J., et al. Exp. Cell Res. 315(20):3477-3485(2009)Frizzell, K.M., et al. J. Biol. Chem. 284(49):33926-33938(2009)Erdelyi, K., et al. FASEB J. 23(10):3553-3563(2009)Ame, J.C., et al. J. Cell. Sci. 122 (PT 12), 1990-2002 (2009) :Uchiumi, F., et al. Genes Cells 13(12):1229-1247(2008)